Literature DB >> 4107267

Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema.

F S Rosen, C A Alper, J Pensky, M R Klemperer, V H Donaldson.   

Abstract

Normal human serum contains 18 +/-5 mg/100 ml of C1 esterase inhibitor (alpha-2 neuraminoglycoprotein) as estimated by immunochemical means. Of 118 patients with hereditary angioneurotic edema, the sera of 80, from 42 kindred, contained a mean concentration of 3.15 mg/100 ml or 17.5% of normal. The mean serum concentration in 35 patients in 7 other kindred was 20 mg/100 ml or 111% of normal, and 3 patients in another kindred contained over 80 mg/100 ml or greater than 400% of normal. The nonfunctional inhibitors in patients' sera of these eight kindred were identical with normal C1 esterase inhibitor by Ouchterlony analysis, but they were different from normal and from each other with respect to their electrophoretic mobility, their capacity to bind C1 esterase, and their ability to inhibit esterolysis of N-acetyl-tyrosine-ethylester.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4107267      PMCID: PMC292148          DOI: 10.1172/JCI106708

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

Authors:  V H DONALDSON; R R EVANS
Journal:  Am J Med       Date:  1963-07       Impact factor: 4.965

3.  STUDIES ON HUMAN C'1-ESTERASE. I. PURIFICATION AND ENZYMATIC PROPERTIES.

Authors:  A L HAINES; I H LEPOW
Journal:  J Immunol       Date:  1964-03       Impact factor: 5.422

4.  Partial purification of a serum inhibitor of C'1-esterase.

Authors:  J PENSKY; L R LEVY; I H LEPOW
Journal:  J Biol Chem       Date:  1961-06       Impact factor: 5.157

5.  Immunofixation electrophoresis: a technique for the study of protein polymorphism.

Authors:  C A Alper; A M Johnson
Journal:  Vox Sang       Date:  1969-11       Impact factor: 2.144

6.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

7.  Enzymatic and immunochemical estimation of C'1 esterase inhibitor in sera from patients with hereditary angioneurotic edema.

Authors:  A B Laurell; J Lindegren; I Malmros; H Mårtensson
Journal:  Scand J Clin Lab Invest       Date:  1969-10       Impact factor: 1.713

8.  Inheritance of human alpha-1-acid glycoprotein (orosomucoid) variants.

Authors:  A M Johnson; K Schmid; C A Alper
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

9.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

10.  Human serum inhibitor of C'1 esterase: identity with alpha-2-neuraminoglycoprotein.

Authors:  J Pensky; H G Schwick
Journal:  Science       Date:  1969-02-14       Impact factor: 47.728

View more
  45 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.

Authors:  M Cugno; J Nuijens; E Hack; A Eerenberg; D Frangi; A Agostoni; M Cicardi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 3.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M M Frank
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

5.  Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene.

Authors:  N J Levy; N Ramesh; M Cicardi; R A Harrison; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

7.  Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon.

Authors:  T Ariga; T Igarashi; N Ramesh; R Parad; M Cicardi; A E Davis
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

8.  Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.

Authors:  J Alsenz; J D Lambris; K Bork; M Loos
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

9.  Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema.

Authors:  D Frangi; M Cicardi; A Sica; F Colotta; A Agostoni; A E Davis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.

Authors:  J Kramer; Y Katz; F S Rosen; A E Davis; R C Strunk
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.